Latest Intelligence on Genomics, Proteomics and Pharmacogenomics

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Celera: u-turn on gene database

Celera will now focus on drug discovery, following in the footsteps of Millennium, HGS and Incyte. In the short term, it will be dependent on license payments from existing customers and from Applied Biosystems for revenues. Its long-term success, however, will be dependent on using its genomics and proteomics resources to produce successful drugs.

Published By Datamonitor
23 Apr 2002
CommentWire
CommentWire

Cambridge Antibody Technology: playing catch-up

Published By Datamonitor
23 May 2001
Expert View
Expert View

Bye bye blockbuster!

Published By Datamonitor
20 Oct 2000
CommentWire
CommentWire

BMS/Pharmagene: investing in gene expression

Published By Datamonitor
05 Sep 2001
CommentWire
CommentWire

BMS/Celera: drug discovery to get shorter

Hot on the heels of last month's obesity research deal between Merck and deCODE, BMS and Celera have agreed to team up to develop novel cardiovascular and diabetes drugs. Both partnerships are attempts to accelerate the drug discovery process in cardiovascular diseases - increasingly important as the costs of clinical development continue to rise.

Published By Datamonitor
09 Oct 2002
CommentWire
CommentWire

Biotechnology: FDA rule changes could boost generics

The FDA's review of current good manufacturing practice (cGMP) seeks to improve standards of drug manufacture. At the same time, the regulations should reduce confusion over biotech-derived drug products. These changes may open the door to greater use of new manufacturing methods and long term, greater opportunities for biogenerics.

Published By Datamonitor
28 Aug 2002
CommentWire
CommentWire

Bayer/CuraGen: billion-dollar genomics alliance

Published By Datamonitor
19 Jan 2001
CommentWire
CommentWire

Aventis: promising early stage results for FGF-1

Published By Datamonitor
13 Jun 2001
CommentWire
CommentWire

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor
18 Nov 2002
CommentWire
CommentWire

Abgenix: a new trial for promising cancer drug

Abgenix's drug could have a promising future. If the compound can improve upon the side effect profile of Roche/Genentech's benchmark monoclonal antibody Herceptin (trastuzumab), as well as gaining further indications, it is likely to become a key player within this field of anticancer treatments.

Published By Datamonitor
07 Jan 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.